Cited by 690Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 46 of the 51 references it cites were found in a registry or an index.

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Open access

Scagliotti, Giorgio, Hanna, Nasser, Fossella, Frank, Sugarman, Katherine, Blatter, Johannes, Peterson, Patrick, Simms, Lorinda, Shepherd, Frances A.·2009·The Oncologist

DOI 10.1634/theoncologist.2008-0232

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. METHODS: One study tested pemetrexed versus docetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (OS) and progression-free survival (PFS). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-adjusted between-arm hazard ratios (HRs). RESULTS: In both studies, treatment arms were well balanced for histology. THIs were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups. CONCLUSIONS: The consistency of these results across studies confirms the predictive effect of histology for pemetrexed and the survival advantage for pemetrexed in patients with nonsquamous histology. These analyses suggest pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, pemetrexed may be preferable to other agents for treatment of patients with nonsquamous NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2008-0232

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citation
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079

Show all 51 references

Research works printed but not linked: 2

Jiroutek, 1998, Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992, Proc Am Soc Clin Oncol, 17, 461a
National Cancer Institute, 1999, Common Toxicity Criteria v2.0 (CTC)

Sorted by citations

Items 201–300 of 687

Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer
Lee, H. Y., Ahn, H. K., Jeong, J. Y., Kwon, M. J., Han, J., Sun, J., Ahn, J. S., Park, K., Choi, Y., & Ahn, M. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.10.002 · Cited by 33
Advances in chemotherapy in advanced non-small-cell lung cancer
Maione, P., Rossi, A., Sacco, P. C., Bareschino, M. A., Schettino, C., & Gridelli, C. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.511615 · Cited by 33
The Machine Learning Model for Distinguishing Pathological Subtypes of Non-Small Cell Lung Cancer
Zhao, H., Su, Y., Wang, M., Lyu, Z., Xu, P., Jiao, Y., Zhang, L., Han, W., Tian, L. H., & Fu, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.875761 · Cited by 36
Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study
Sun, Y. K., Wu, Y.-L. L. C., Zhou, C., Zhang, L., Zhang, L., Liu, X.-Y., Yu, S., Jiang, G., Li, K., Qin, S., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.10.015 · Cited by 33
Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer
Choy, H., Schwartzberg, L. S., Dakhil, S. R., Garon, E. B., Gerber, D. E., Choksi, J. K., Govindan, R., Peng, G., Koustenis, A. G., Treat, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a02546 · Cited by 33
Everolimus in Combination with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Chemotherapy: A Phase I Study Using a Novel, Adaptive Bayesian Dose-Escalation Model
Vansteenkiste, J., Solomon, B., Boyer, M. J., Wolf, J., Miller, N., Scala, L. D., Pylvaenaeinen, I., Petrovic, K., Dimitrijević, S., Anrys, B., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307ede · Cited by 33
Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma
Lustgarten, D. S., Deshpande, C. G., Aggarwal, C., Wang, L.-C., Saloura, V., Vachani, A., Wang, L.-P., Litzky, L. A., Feldman, M. D., Creaney, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318283da3e · Cited by 33
Validation and target gene screening of hsa-miR-205 in lung squamous cell carcinoma
Huang, W., Jin, Y., Yuan, Y., Bai, C., Wu, Y., Zhu, H., & Lu, S. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20121121 · Cited by 33
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer
Barrera, C., Corredor, G., Viswanathan, V. S., Ding, R., Toro, P., Fu, P., Buzzy, C. A., Lu, C. Y., Velu, P., Zens, P., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00403-x · Cited by 34
Glucocorticoid Receptor Status Is a Principal Determinant of Variability in the Sensitivity of Non–Small-Cell Lung Cancer Cells to Pemetrexed
Patki, M., Gadgeel, S. M., Huang, Y., McFall, T. B., Shields, A. F., Matherly, L. H., Bepler, G., & Ratnam, M. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000111 · Cited by 32
Novel agents in development for advanced non-small cell lung cancer
Stinchcombe, T. E. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014532510 · Cited by 32
Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
Melosky, B. L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00256 · Cited by 33
A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non‐small cell lung cancers
Koh, J., Go, H., Kim, M., Jeon, Y. K., Chung, J.-H., & Chung, D. H. (2014) · Histopathology · doi:10.1111/his.12507 · Cited by 32
Cost-Effectiveness of Continuation Maintenance Pemetrexed After Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Estimates From the Perspective of the Chinese Health Care System
Zeng, X., Peng, L., Li, J., Chen, G., Tan, C., Wang, S., Wan, X., Ouyang, L., & Zhao, Z. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.12.013 · Cited by 32
Sorafenib in non-small cell lung cancer
Zhang, J. J., Gold, K. A., & Kim, E. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.699039 · Cited by 32
Epigenetic Therapy in Lung Cancer – Role of microRNAs
Rothschild, S. I. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00158 · Cited by 31
Transcriptome analysis of distinct long non-coding RNA transcriptional fingerprints in lung adenocarcinoma and squamous cell carcinoma
Wei, Y., & Zhang, X. (2016) · Tumor Biology · doi:10.1007/s13277-016-5422-2 · Cited by 31
Circulating and extracellular vesicle-derived microRNAs as biomarkers in bone-related diseases
Huber, J., Longaker, M. T., & Quarto, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168898 · Cited by 31
Critical comments for roles of biomarkers in the diagnosis and treatment of cancer
Saijo, N. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.02.004 · Cited by 31
Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer
Stasi, I., & Cappuzzo, F. (2014) · Translational Respiratory Medicine · doi:10.1186/2213-0802-2-2 · Cited by 30
Neoadjuvant Therapy in Non–Small Cell Lung Cancer
Zheng, Y., Jaklitsch, M. T., & Bueno, R. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2016.02.010 · Cited by 29
Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells
Liao, K., Wei, C.-L., Chen, J., Zheng, H., Chen, W.-C., Wu, C.-H., Wang, T., Peng, Y.-S., Chang, P.-Y., & Lin, Y. (2016) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2016.09.031 · Cited by 30
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study
Gottfried, M., Bennouna, J., Bondarenko, I., Douillard, J., Heigener, D. F., Krzakowski, M. J., Mellemgaard, A., Novello, S., Орлов, С. В., Summers, Y., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0517-2 · Cited by 30
Brain Metastases as the Primary Site of Relapse in Two Randomized Phase III Pemetrexed Trials in Advanced Non–Small-Cell Lung Cancer
Ortuzar, W. I., Hanna, N. H., Pennella, E. J., Peng, G., Langer, C. J., Monberg, M., & Scagliotti, G. V. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.05.007 · Cited by 30
Self-citation
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population
Asukai, Y., Valladares, A., Camps, C., Wood, E. M., Taipale, K., Arellano, J., Cassinello, A., Sacristán, J. A., & Dilla, T. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-26 · Cited by 30
Are EUS–FNA and EBUS–TBNA specimens reliable for subtyping non-small cell lung cancer?
Tournoy, K. G., Carprieaux, M., Deschepper, E., van Meerbeeck, J. P., & Praet, M. M. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.09.004 · Cited by 29
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines
de Marinis, F., Rossi, A., Maïo, M. D., Ricciardi, S., & Gridelli, C. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.02.022 · Cited by 30
Primary Tumor Xenografts of Human Lung Adeno and Squamous Cell Carcinoma Express Distinct Proteomic Signatures
Wei, Y., Tong, J., Taylor, P. P., Strumpf, D., Ignatchenko, V., Pham, N., Yanagawa, N., Liu, G., Jurišica, I., Shepherd, F. A., et al. (2010) · Journal of Proteome Research · doi:10.1021/pr100491e · Cited by 29
Self-citation
Biological Prognostic and Predictive Factors in Lung Cancer
Rossi, A., Galetta, D., & Gridelli, C. (2009) · Oncology · doi:10.1159/000258500 · Cited by 29
CLCA2 as a Novel Immunohistochemical Marker for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung
Shinmura, K., Igarashi, H., Kato, H., Kawanishi, Y., Inoue, Y., Nakamura, S., Ogawa, H., Yamashita, T., Kawase, A., Funai, K., et al. (2014) · Disease Markers · doi:10.1155/2014/619273 · Cited by 29
Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer: An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial
Belani, C. P., Wu, Y.-L. L. C., Chen, Y.-M., Kim, J.-H., Yang, S. L., Zhang, L., Peterson, P. M., & Orlando, M. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823d4f9d · Cited by 28
Self-citation
TS expression predicts postoperative recurrence in adenocarcinoma of the lung
Shimokawa, H., Uramoto, H., Onitsuka, T., Iwata, T., Nakagawa, M., Ono, K., & Hanagiri, T. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.08.024 · Cited by 28
YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells
Wang, Y., Guo, S., Li, D., Tang, Y., Li, L., Su, L., & Liu, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2436-x · Cited by 28
LINC01503/miR-342-3p facilitates malignancy in non-small-cell lung cancer cells via regulating LASP1
Shen, Q., Sun, Y., & Xu, S. (2020) · Respiratory Research · doi:10.1186/s12931-020-01464-3 · Cited by 28
Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis
Carroll, R., Bortolini, M., Calleja, A., Munro, R. E. J., Kong, S., Daumont, M., Penrod, J. R., Lakhdari, K., Lacoin, L., & Cheung, W. Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09342-5 · Cited by 28
Systemic Therapies in Metastatic Non-Small-Cell Lung Cancer with Emphasis on Targeted Therapies: The Rational Approach
Hirsh (2010) · Current Oncology · doi:10.3747/co.v17i2.549 · Cited by 28
CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy
Sone, K., Oguri, T., Nakao, M., Kagawa, Y., KUROWAKA, R., Furuta, H., Fukuda, S., Uemura, T., TAKAKUWA, O., Kanemitsu, Y., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11402 · Cited by 28
Molecular Pathology of Lung Cancer
Solis, L. M., & Wistuba, I. I. (2012) · Springer eBooks · doi:10.1007/978-1-4419-0787-5_14 · Cited by 27
Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
Krawczyk, P. A., Kucharczyk, T., Kowalski, D. M., Powrózek, T., Ramlau, R., Kalinka‐Warzocha, E., Winiarczyk, K., Knetki‐Wróblewska, M., Wojas‐Krawczyk, K., Kałakucka, K., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1756-6 · Cited by 27
Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non–Small-Cell Lung Cancer: Implications for Therapy
Maus, M. K. H., Mack, P. C., Astrow, S. H., Stephens, C. L., Zeger, G. D., Grimminger, P., Hsiang, J., Huang, E. C., Li, T., Lara, P. N., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318287c3c5 · Cited by 27
Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens
Zakowski, M. F., Rekhtman, N., Auger, M., Booth, C. N., Crothers, B. A., Ghofrani, M., Khalbuss, W. E., Laucirica, R., Moriarty, A. T., Tabatabai, Z. L., et al. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0316-oa · Cited by 27
A Call for the Aggressive Treatment of Oligometastatic and Oligo-Recurrent Non-Small Cell Lung Cancer
Patel, P. R., Yoo, D. S., Niibe, Y., Urbanic, J. J., & Salama, J. K. (2012) · Pulmonary Medicine · doi:10.1155/2012/480961 · Cited by 27
Maintenance therapy in NSCLC: why? To whom? Which agent?
Novello, S., Milella, M., Tiseo, M., Banna, G. L., Cortinovis, D. L., Maïo, M. D., Garassino, M. C., Maione, P., Martelli, O., Vavalà, T., et al. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-50 · Cited by 28
Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
Cumberbatch, M., Tang, X., Beran, G. J., Eckersley, S., Wang, X., Ellston, R. P. A., Dearden, S. P., Cosulich, S. C., Smith, P. D., Behrens, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1638 · Cited by 27
Identification of microRNA differentially expressed in three subtypes of non-small cell lung cancer and in silico functional analysis
Hu, Y., Wang, L., Gu, J., Qu, K., & Wang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20218 · Cited by 27
CT-Guided Transthoracic Biopsy of Pulmonary Lesions: Diagnostic versus Nondiagnostic Results
Borelli, C., Vergara, D., Simeone, A., Pazienza, L., Castorani, G., Graziano, P., Micco, C. D., Quarato, C. M. I., & Sperandeo, M. (2022) · Diagnostics · doi:10.3390/diagnostics12020359 · Cited by 26
Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: A systematic review of completed and ongoing studies
Choy, H., Gerber, D. E., Bradley, J. D., Iyengar, P., Monberg, M., Treat, J., Govindan, R., Koustensis, A., Barker, S. S., & Obasaju, C. K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.003 · Cited by 26
Large cell carcinoma of lung: On the verge of extinction?
Weissferdt, A. (2014) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2014.06.005 · Cited by 27
Comparison of Patient Outcomes According to Histology Among Pemetrexed-Treated Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer in Two Phase II Trials
Zinner, R., Novello, S., Peng, G., Herbst, R. S., Obasaju, C. K., & Scagliotti, G. V. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.017 · Cited by 26
Self-citation
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer
Rossi, G., Alama, A., Genova, C., Rijavec, E., Tagliamento, M., Biello, F., Coco, S., Bello, M. G. D., Boccardo, S., & Grossi, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1536746 · Cited by 26
Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)
Zinner, R., Visseren‐Grul, C., Spigel, D. R., & Obasaju, C. K. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3219 · Cited by 25
Less Toxic Chemotherapy Improves Uptake of All Lines of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A 10-Year Retrospective Population-Based Review
Ho, C., Ramsden, K., Zhai, Y., Murray, N., Sun, S. B., Melosky, B. L., & Laskin, J. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000225 · Cited by 25
Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study
Blumenschein, G. R., Ciuleanu, T., Robert, F., Groen, H. J. M., Usari, T., Ruiz-García, A., Tye, L., Chao, R. C., & Juhász, E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31825cca1c · Cited by 26
Tubulin inhibitors in non-small cell lung cancer: looking back and forward
Ferrara, R., Pilotto, S., Peretti, U., Caccese, M., Kinspergher, S., Carbognin, L., Karachaliou, N., Rosell, R., Tortora, G., & Bria, E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1157581 · Cited by 25
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study
Niho, S., Yoshida, T., Akimoto, T., Sakamaki, K., Ono, A., Seto, T., Nishio, M., Yamamoto, N., Hida, T., Okamoto, H., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.01.008 · Cited by 25
Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges
Langer, C. J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.09.004 · Cited by 24
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review
Kulkarni, S., Vella, E. T., Coakley, N., Cheng, S. Y.-S., Gregg, R. W., Ung, Y., & Ellis, P. M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.007 · Cited by 24
Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification
Yeh, S., Chang, C.-A., Li, C., Wang, L. H.-C., & Chen, B. (2019) · Oncotarget · doi:10.18632/oncotarget.26940 · Cited by 24
Host-guest inclusion for enhancing anticancer activity of pemetrexed against lung carcinoma and decreasing cytotoxicity to normal cells
Chen, J., Zhang, Y., Zhang, Y., Zhao, L., Chen, L., Chai, Y., Meng, Z., Jia, X., Meng, Q., & Li, C. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.03.079 · Cited by 24
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials
Scagliotti, G. V., Gridelli, C., de Marinis, F., Thomas, M., Dediu, M., Pujol, J.-L., Manegold, C., Antonio, B. S., Peterson, P. M., John, W. J., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.005 · Cited by 24
Self-citation
Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
Berge, E. M., Lu, X. J. D., Maxson, D. A., Barón, A. E., Gadgeel, S. M., Solomon, B., Doebele, R. C., Varella-Garcia, M., & Camidge, D. R. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.06.005 · Cited by 24
Molecular Testing in Lung Cancer: The Time Is Now
Cheng, H., Xu, X., Costa, D. B., Powell, C. A., & Halmos, B. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0118-z · Cited by 24
Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer
Tamiya, A., Tamiya, M., Shiroyama, T., Kanazu, M., Hirooka, A., Tsuji, T., Morishita, N., Asami, K., Suzuki, H., Okamoto, N., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds544 · Cited by 24
A prediction model for distinguishing lung squamous cell carcinoma from adenocarcinoma
Li, H., Jiang, Z., Leng, Q., Bai, F., Wang, J., Ding, X., Li, Y., Zhang, X., Fang, H., Yfantis, H. G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17038 · Cited by 24
ERCC1 as Predictor of Platinum Benefit in Non–Small-Cell Lung Cancer
Postel-Vinay, S. C., & Soria, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5053 · Cited by 24
Fibulin-1 functions as a prognostic factor in lung adenocarcinoma
Yuan, C., Liu, J., Yin, H.-B., Liu, Y., & Liu, J. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv094 · Cited by 23
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
Yang, J. C., Mok, T. S. K., Han, B., Orlando, M., Puri, T., & Park, K. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.013 · Cited by 23
Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Biswas, T., Kang, K. H., Gawdi, R., Bajor, D. J., Machtay, M. X., Jindal, C., & Efird, J. T. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17217995 · Cited by 23
Pemetrexed in advanced non-small cell lung cancer
Gridelli, C., Maione, P., Rossi, A., Bareschino, M. A., Schettino, C., Sacco, P. C., & Zeppa, R. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.553281 · Cited by 22
Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?
Massutí, B., Sánchez, J. M., Hernándo, F., Karachaliou, N., & Rosell, R. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.06 · Cited by 22
Integrated Bioinformatics Analysis of Hub Genes and Pathways in Anaplastic Thyroid Carcinomas
Gao, X., Wang, J., & Zhang, S. (2019) · International Journal of Endocrinology · doi:10.1155/2019/9651380 · Cited by 22
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)
Fukuda, M., Kitazaki, T., Ogawara, D., Ichiki, M., Mukae, H., Maruyama, R., Nakagaki, N., Shimada, M., Ikeda, T., Kishimoto, J., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.008 · Cited by 22
Prediction of Target-Drug Therapy by Identifying Gene Mutations in Lung Cancer With Histopathological Stained Image and Deep Learning Techniques
Huang, K., Mo, Z., Zhu, W. Q., Liao, B., Yang, Y., & Wu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642945 · Cited by 22
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials
Noonan, K. L., Ho, C., Laskin, J. J., & Murray, N. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000667 · Cited by 24
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
Gridelli, C., Rossi, A., Bareschino, M. A., Schettino, C., Sacco, P. C., & Maione, P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003767434 · Cited by 22
Improving the Subtype Classification of Non-small Cell Lung Cancer by Elastic Deformation Based Machine Learning
Gao, Y., Song, F., Zhang, P., Liu, J., Cui, J., Ma, Y., Zhang, G., & Luo, J. (2021) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-021-00455-0 · Cited by 21
Artificial intelligence-based rapid on-site cytopathological evaluation for bronchoscopy examinations
Ai, D., Hu, Q., Chao, Y., Fu, C.-C., Yuan, W., Lv, L., Ye, D., Li, C., Ye, M., Zhang, Y., et al. (2022) · Intelligence-Based Medicine · doi:10.1016/j.ibmed.2022.100069 · Cited by 21
Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy
Stinchcombe, T. E. (2014) · Medical Oncology · doi:10.1007/s12032-014-0960-1 · Cited by 20
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer
Toffalorio, F., Giovannetti, E., Pas, T. M. D., Radice, D., Pelosi, G., Manzotti, M., Minocci, D., Spaggiari, L., Spitaleri, G., Noberasco, C., et al. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.53 · Cited by 21
Therapeutic management of ALK+nonsmall cell lung cancer patients
Duchemann, B., Friboulet, L., & Besse, B. (2015) · European Respiratory Journal · doi:10.1183/09031936.00236414 · Cited by 22
Suitability of Computed Tomography-Guided Biopsy Specimens for Subtyping and Genotyping of Non–Small-Cell Lung Cancer
Hsiao, S.-H., Chung, C., Lee, C., Chen, W., Chou, Y., Wu, Z.-H., Chen, Y.-C., & Lin, S. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.06.002 · Cited by 21
Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients
Zhang, G., Jiao, S., & Meng, Z. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-38 · Cited by 21
Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry
Chargin, A., Morgan, R., Sundram, U. N., Shults, K., Tsay, E. L., Ratti, N. P., & Patterson, B. K. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1889-3 · Cited by 21
Clinical significance of blood‑based miRNAs as biomarkers of non‑small cell lung cancer (Review)
Li, L., Sun, Y., Feng, M., Wang, L., & Liu, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8469 · Cited by 21
Advances in adjuvant systemic therapy for non-small-cell lung cancer
Leong, D. C. W. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.633 · Cited by 20
Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)
Obasaju, C. K., Bowman, L., Wang, P., Shen, W., Winfree, K. B., Smyth, E. N., Boye, M. E., John, W. J., Brodowicz, T., & Belani, C. P. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt123 · Cited by 20
Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic
Socinski, M. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.017 · Cited by 20
Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis
Ni, Y., Xiao, H., Tian, R.-H., Zhang, Z., & Du, K. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s96160 · Cited by 20
Radiation Therapy as a Backbone of Treatment of Locally Advanced Non-Small Cell Lung Cancer
Laine, A. M., Westover, K. D., & Choy, H. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.012 · Cited by 20
Clinical significance of the ‘not otherwise specified’ subtype in candidates for resectable non-small cell lung cancer
Tane, S., Nishio, W., Ogawa, H., Hokka, D., Tane, K., Tanaka, Y., Tauchi, S., Uchino, K., Sakai, Y., Ohbayashi, C., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2302 · Cited by 20
Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges
Pallis, A. G., & Syrigos, K. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.006 · Cited by 20
Best practice in the treatment of advanced squamous cell lung cancer
Ang, Y. L. E., Tan, H.-L., & Soo, R. A. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815581147 · Cited by 20
Update on nonsmall cell lung cancer
Zalcman, G., Bergot, E., & Lechapt, E. (2010) · European Respiratory Review · doi:10.1183/09059180.00006610 · Cited by 20
Real-World Outcomes in Patients with Alk-Positive Non-Small Cell Lung Cancer Treated with Crizotinib
Davis, K. L., Kaye, J. A., Masters, E. T., & Iyer, S. S. (2018) · Current Oncology · doi:10.3747/co.25.3723 · Cited by 20
The Efficacy of PD-1/PD-L1 Inhibitors in Advanced Squamous-Cell Lung Cancer: A Meta-Analysis of 3112 Patients
Chen, R., Zhou, J., Cao, Y., Li, S., Li, Y., Jiang, M., Lu, D., Peng, L., & Lin, L. (2019) · Immunotherapy · doi:10.2217/imt-2019-0101 · Cited by 20
Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
Ikeda, N., Nagase, S., & Ohira, T. (2009) · PubMed · Cited by 20
Can MicroRNAs Improve the Management of Lung Cancer Patients? A Clinician's Perspective
Tufman, A., Tian, F., & Huber, R. M. (2013) · Theranostics · doi:10.7150/thno.6615 · Cited by 19
Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor
Patki, M., McFall, T. B., Rosati, R., Huang, Y., Malysa, A., Polin, L., Fielder, A. M., Wilson, M. R., Lonardo, F., Back, J. B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34475-8 · Cited by 19
Association between depth of response and survival in patients with advanced‐stage non–small cell lung cancer treated with first‐line chemotherapy
Morgensztern, D., Ko, A., O'Brien, M. E. R., Ong, T. J., Waqar, S. N., Socinski, M. A., Postmus, P. E., & Bhore, R. (2019) · Cancer · doi:10.1002/cncr.32114 · Cited by 19
Molecular Characterization by Immunocytochemistry of Lung Adenocarcinoma on Cytology Specimens
Moreira, A. L., & Hasanovic, A. (2012) · Acta Cytologica · doi:10.1159/000339794 · Cited by 19

Authors: Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A.
Affiliations: University of Turin (IT)
Indiana University Indianapolis (US)
The University of Texas MD Anderson Cancer Center (US)
Eli Lilly (United States) (US)
Eli Lilly (Germany) (DE)
Eli Lilly (Canada) (CA)
University of Toronto (CA)
Corresponding author: Scagliotti, Giorgio
ORCID: Scagliotti, Giorgio
Hanna, Nasser
Peterson, Patrick
Shepherd, Frances A.
Venue: The Oncologist
Publisher: Oxford University Press (OUP)
Published: 2009-02-16
Volume: 14
Issue: 3
Pages: 253-263
ISSN: 1083-7159 (ISSN-L)
1549-490X
DOI: 10.1634/theoncologist.2008-0232
OpenAlex: W2139939379
Cited by: 690
References: 51
Citations by year: 2026: 5 · 2025: 8 · 2024: 10 · 2023: 15 · 2022: 21 · 2021: 15 · 2020: 27 · 2019: 29 · 2018: 30 · 2017: 42 · 2016: 46 · 2015: 41 · 2014: 69 · 2013: 72 · 2012: 71
FWCI: 72.97
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: The Oncologist (publishedVersion)
PubMed (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
INFM-OAR (INFN Catania) (submittedVersion, other-oa)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: pemetrexed, non-small cell lung cancer, tumor histology, squamous cell carcinoma, docetaxel, overall survival, progression-free survival, predictive biomarkers
MeSH terms: Pemetrexed, Docetaxel, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Randomized Controlled Trials as Topic, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks